Syncromune® Appoints Kerri-Ann Millar As Chief Financial Officer To Boost Business And Clinical Pipeline

Syncromune® Inc., a clinical-stage biopharmaceutical company focused on personalized immunotherapy for solid tumors, has announced the appointment of Kerri-Ann Millar, CPA, as its new Chief Financial Officer. Ms. Millar brings over 20 years of financial leadership experience in the life sciences industry, with a strong background in supporting biotech companies through critical growth stages, including IPOs, fundraising, and product commercialization. Her appointment comes as Syncromune prepares to advance its lead investigational therapy, SYNC-T SV-102, into the Phase 2a LEGION-100 clinical trial for metastatic castration-resistant prostate cancer. In her new role, Ms. Millar will lead the company’s financial strategy, strengthen its financial operations, and support ongoing clinical development efforts.

Eamonn Hobbs, Co-Founder, President and CEO of Syncromune, said in a statement, “Kerri-Ann brings a rare combination of financial rigor, operational leadership, and deep industry expertise that makes her an exceptional fit for Syncromune.Her track record leading companies through critical phases of fundraising, strategic transactions, and organizational scale-up through commercialization will be instrumental as we continue advancing our pipeline and expanding operations and we’re thrilled to welcome her to the leadership team.”

Ms. Millar, mentioned, “Syncromune is pursuing a bold vision to transform how metastatic cancers are treated through a truly novel immunotherapy platform. I’m excited to join a team that is innovative, mission-driven, and deeply committed to developing solutions to help patients with advanced cancers. I look forward to supporting the company’s continued growth and executing a financial strategy that enables us to deliver our therapy to patients in need.”

Before joining Syncromune, Ms. Millar was the CFO of Cue Biopharma, a publicly listed immunotherapy company, where she oversaw finance, investor relations, human resources, and IT. During her time there, she played a key role in raising over $300 million in funding, including leading the company’s initial public offering. She has also held senior finance roles at Flexion Therapeutics supporting its IPO, clinical progress, and commercial launch and at Curis, Inc., where she managed regulatory compliance and SEC reporting. She began her career in public accounting with PricewaterhouseCoopers. Ms. Millar holds a Bachelor of Science in Accounting from Boston University and is a Certified Public Accountant in Massachusetts. Her experience and leadership are expected to play a vital role in Syncromune’s next phase of growth and development.